Rifaximin, used for hepatic encephalopathy prophylaxis, differs from systemic rifamycins in a pharmacokinetically crucial manner. This difference explains why rifaximin does not produce systemic antibiotic adverse effects:

• A Rifaximin is metabolised by intestinal flora to a harmless product before absorption
• B Rifaximin has very low oral bioavailability (<0.4%) due to its pyridoimidazole ring substitution making it highly polar and unable to cross intestinal epithelium — it acts entirely in the gut lumen ✓
• C Rifaximin undergoes complete first-pass hepatic extraction, converting to an inactive sulphoxide in the liver before reaching systemic circulation
• D Rifaximin is a P-glycoprotein substrate that is rapidly effluxed back into the gut lumen from enterocytes, preventing systemic absorption

Explanation

Rifaximin is a structural analogue of rifamycin SV with a benzimidazole ring system that makes the molecule highly polar and essentially non-absorbable from the intact gastrointestinal mucosa (oral bioavailability <0.4% in healthy individuals). This confines its antibacterial activity to the gut lumen, reducing ammonia-producing colonic bacteria and modulating the gut microbiome in patients with hepatic encephalopathy (HE), without systemic drug exposure or systemic side effects. It does not undergo microbial inactivation, significant hepatic first-pass, or P-gp-mediated efflux as the primary mechanism — very low passive absorption is the key.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.